Scroll to top

Appendix 4C & Activity Report

Melbourne, Australia, 28 January 2021

CLINUVEL PHARMACEUTICALS LTD today announced its Appendix 4C – Quarterly Cashflow Report and Activity Report for the period 01 October to 31 December 2020. All figures are rounded and reported in Australian dollars.   

KEY CASH FLOW HIGHLIGHTS Q2 FY21:
Cash Receipts
$5,266,000
Net operating cash flow
$1,293,000
Cash Flow 01 Jan-31 Dec 2020
$33,053,000

Operating Conditions & The Global Economy

The coronavirus pandemic is causing anguish with the ongoing loss of human life, and the world is experiencing the largest contraction since the Great Depression of 1929. Despite some economies showing signs of resilience, the pace of recovery is proving to be disparate.

In this unprecedented environment where hospital and medical supplies face new challenges, CLINUVEL continues to strengthen its business and balance sheet. In the current financial year CLINUVEL has expanded both its commercial operation in the USA and its research and development program, without having to enter equity or debt financing. Following a fourth consecutive annual profit in the financial year ending 30 June 2020, and a positive cashflow outcome in the 2020 September quarter, the Company continues to record positive cash receipts in the 2020 December quarter leading to an increase in cash reserves.

Commentary

“The continued performance of the Group stems from our measured strategy, consistent execution, and treatment demand from both the USA and Europe, which have contributed to a new high in annual cash receipts,” CLINUVEL’s Chief Financial Officer, Mr Darren Keamy said.

“Against the ongoing backdrop of economic uncertainty, and in a quarter where cash receipts are historically lower, reflecting the seasonal demand, we have now been able to deliver a positive net cash result in the December quarter, the first in the Company’s history.

“As of today, CLINUVEL is in a good position to pursue further investments in its R&D and clinical programs, aiming to deliver long-term value while building out the CLINUVEL Group of companies,” Mr Keamy said.

Strong Cash Receipts & Net Cash

Cash receipts of $5,266,000 reflect contribution from the commercial distribution of SCENESSE® (afamelanotide 16 mg) in the United States and, the European Economic Area. Net cash flow from operating activities was $1,293,000 in the quarter.

Annual Trend in Cash Receipts & Expenditures

Graph 1 shows CLINUVEL’s annual cash receipts at each quarterly timepoint since the June quarter 2017 (on a rolling annual basis). The last two quarters of 2020 include cash receipts from the distribution of SCENESSE® in the US which commenced in April 2020. Rolling annual cash receipts to 31 December 2020 from the distribution of SCENESSE® were $33,053,000 – the highest since commercial operations commenced in June 2016.

Whilst distribution of SCENESSE® in the USA commenced in April 2020, the cash receipt cycle is longer than in Europe, in part due to the decentralised reimbursement system. As part of the administrative handling required by all parties in the billing and reimbursement process, CLINUVEL is recording cash receipts in cases which are longer than 90 days from invoice date. This period is expected to shorten as insurers include the new treatment within their administrative databases.

Controlled Growth in Expenditures

Annual operating expenditures have been controlled and gradually increase over time to support the Group’s future growth, including head count and supply chain costs. Expenditures from net operating activities were $4,111,000 in the December quarter 2020; these do not include the impact from other receipts, such as interest received from placing cash reserves on term deposit. Further growth in the business, including the preparation of its clinical program in DNA regeneration and stroke (AIS) and research & development are in line with the Company’s strategic plan. Graph 1 illustrates an expected upward growth to overall operating expenditures to realise CLINUVEL’s plans.

Review of Key Activities:

The Group continued to develop its commercial operations in the December quarter 2020 in Europe and the USA. Research and development activities were expanded with a focus on novel treatments for patients with severe genetic and vascular disorders who lack therapeutic alternatives. After some deferral of orders or reduced order sizes in the initial months of 2020 due to the coronavirus pandemic in Europe, demand has largely normalised and patient adherence to SCENESSE® treatment remains high. The Company’s key activities in the quarter included:
    • Progress in the DNA Repair Program with the completion of treatment of the first xeroderma pigmentosum (XP) patient with SCENESSE® to evaluate the product’s safety and satisfy the request from authorities. The XPC patient tolerated treatment well, providing the basis on which a Phase II study (CUV150) will proceed in a group of six XP-C patients, subject to ethics committee and other approvals to start during the COVID pandemic.
    • Approval of SCENESSE® by the Australian Therapeutic Goods Administration to treat adult patients with EPP.
    • Expansion of the research and development program to evaluate the effects of afamelanotide, the active ingredient in SCENESSE® , in patients suffering from arterial ischaemic stroke (AIS). Pending COVID restrictions, a pilot Phase II study (CUV801) will commence to administer afamelanotide to up to six AIS patients to evaluate its safety and effectiveness.
    • A strategic update (26 October 2020) to outline the Group’s new divisional structure and expanded research and development program to support the diversification and growth of the Group in pharmaceutical products for unmet medical needs and non-pharmaceutical products for wider healthcare use.
The Company’s announcements on each of these events are available on the CLINUVEL website. Although the Company is not obligated to publish quarterly cash flow results, it elects to continue to do so to keep its investors regularly and periodically updated. A copy of the Appendix 4C – Quarterly Cash Flow Report for the second quarter of FY2021 is attached. Pursuant to Listing Rule 4.7C and as disclosed in Item 6.1 to the attached Appendix 4C, $338,000 was paid in respect to Non-Executive Director and Managing Director fees, while this figure is inclusive of the value of non-monetary benefits.

1 SCENESSE® (afamelanotide 16mg) is approved in the European Union as an orphan medicinal product and  the world’s first systemic photoprotective pharmaceutical for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). SCENESSE® is approved in the USA to increase “pain-free” light exposure in adult EPP patients with a history of phototoxicity.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B​

1.

Cash flows from operating activitiesCurrent quarter $A’000Year to date (6 months) $A'000
1.1Receipts from customers

5,266

17,821

1.2Payments for
(a)    research and development

(154)

(545)

(b)    product manufacturing and operating costs

(1,317)

(2,561)

(c)    advertising and marketing

(97)

(118)

(d)    leased assets

(84)

(170)

(e)    staff costs

(1,861)

(3,773)

(f)     administration and corporate costs

(587)

(1,231)

1.3Dividends received (see note 3)--
1.4Interest received95201
1.5Interest and other costs of finance paid

(6)

(13)

1.6Income taxes paid--
1.7Government grants and tax incentives4381
1.8Other (provide details if material)

(5)

22
1.9Net cash from / (used in) operating activities1,2939,174

2.

Cash flows from investing activitiesCurrent quarter $A’000Year to date (6 months) A$'000
2.1Payments to acquire or for:
(a)    entities--
(b)    businesses--
(c)    property, plant and equipment(145)(795)
(d)    investments--
(e)    intellectual property--
(f)    other non-current assets--
2.2Proceeds from disposal of:
(g)    entities--
(h)    businesses--
(i)    property, plant and equipment--
(j)    investments--
(k)    intellectual property--
(l)     other non-current assets--
2.3Cash flows from loans to other entities--
2.4Dividends received (see note 3)--
2.5Other (provide details if material)--
2.6Net cash from / (used in) investing activities(145)(795)
3.Cash flows from financing activitiesCurrent quarter $A’000Year to date (6 months) A$'000
3.1Proceeds from issues of equity securities (excluding convertible debt securities)--
3.2Proceeds from issue of convertible debt securities--
3.3Proceeds from exercise of options--
3.4Transaction costs related to issues of equity securities or convertible debt securities--
3.5Proceeds from borrowings--
3.6Repayment of borrowings(74)(133)
3.7Transaction costs related to loans and borrowings--
3.8Dividends paid-(1,235)
3.9Other (provide details if material)--
3.10Net cash from / (used in) financing activities(74)(1,368)

4.

Net increase / (decrease) in cash and cash equivalents for the periodCurrent quarter $A’000Year to date (6 months) A$'000
4.1Cash and cash equivalents at beginning of period

72,759

66,747

4.2Net cash from / (used in) operating activities (item 1.9 above)

1,293

9,174

4.3Net cash from / (used in) investing activities (item 2.6 above)(145)(795)
4.4Net cash from / (used in) financing activities (item 3.10 above)(74)(1,368)
4.5Effect of movement in exchange rates on cash held(915)(840)
4.6Cash and cash equivalents at end of period

72,918

72,918

5.

Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accountsCurrent quarter $A’000Year to date (6 months) A$'000
5.1Bank balances

30,448

28,782

5.2Call deposits

42,168

43,620

5.3Bank overdrafts--
5.4Other (provide details)302  357
5.5Cash and cash equivalents at end of quarter (should equal item 4.6 above)

72,918

72,759

6.

Payments to related parties of the entity and their associatesCurrent quarter $A'000
6.1Aggregate amount of payments to related parties and their associates included in item 1338
6.2Aggregate amount of payments to related parties and their associates included in item 2

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

7.

Financing facilitiesTotal facility amount at quarter endAmount drawn at quarter end

Note: the term “facility’ includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.

$A’000$A’000
7.1Loan facilities
7.2Credit standby arrangements
7.3Other (please specify)
7.4Total financing facilities
7.5Unused financing facilities available at quarter end
7.6Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

8.

Estimated cash available for future operating activities$A’000
8.1Net cash from / (used in) operating activities (item 1.9)
8.2Cash and cash equivalents at quarter end (item 4.6)
8.3Unused finance facilities available at quarter end (item 7.5)
8.4Total available funding (item 8.2 + item 8.3)
8.5Estimated quarters of funding available (item 8.4 divided by item 8.1)n/a


Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as “N/A”. Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6If item 8.5 is less than 2 quarters, please provide answers to the following questions:
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?
Answer:
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?
Answer:
8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?
Answer:

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered

Compliance Statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
2 This statement gives a true and fair view of the matters disclosed.

Date: 28 January 2021

Authorised by: Board of Directors of CLINUVEL PHARMACEUTICALS LTD
(Name of body or officer authorising release – see note 4)

Notes:
1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity’s activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: “By the board”. If it has been authorised for release to the market by a committee of your board of directors, you can insert here: “By the [name of board committee – eg Audit and Risk Committee]”. If it has been authorised for release to the market by a disclosure committee, you can insert here: “By the Disclosure Committee”.
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council’s Corporate Governance Principles and Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.

We use cookies to give you the best experience.